Evidence map›Paper›PMID 41147825›Full record

ReviewNEJM evidence2025

Direct-to-Consumer Genetic Testing.

Julianne M O'Daniel, Christine Kobelka, Kimberly Foss, Ann Katherine M Foreman, Laura V Milko

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in NEJM evidence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Julianne M O'DanielDepartment of Medicine, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill.
Christine KobelkaDepartment of Genetics, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill.
Kimberly FossDepartment of Genetics, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill.
Ann Katherine M ForemanDepartment of Genetics, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill.
Laura V MilkoDepartment of Genetics, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill.

Funding

Diversity Supplement: Age-based genomic screening in newborns, infants, and children: a novel paradigm in public health genomicsR01HG012271 · NHGRI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JONATHAN S BERG, Laura Vogel Milko · 2022 to 2026
$4.5M
NHGRI NIH HHS R01 HG012271
6 · The paper itself

Abstract

AbstractDirect-to-consumer genetic testing has become increasingly popular, offering individuals easy access to genetic data without the involvement of health care professionals. However, as availability grows, clinicians face challenges in interpreting and integrating this information into clinical care. This review provides insights for health professionals about the evolving landscape of direct-to-consumer genetic testing, with a focus on test offerings, limitations, challenges, and ethical concerns. It also highlights issues that can arise with direct-to-consumer genetic testing in the pediatric setting. Clinicians can play a pivotal role in guiding patients and families through the complexities of direct-to-consumer genetic testing, ensuring that decisions are informed and risks are minimized.

Indexed as

Direct-To-Consumer Screening and TestingGenetic TestingGenetic CounselingHumans

Identifiers

PMID41147825
PMCPMC13003769

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.